{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:08Z","timestamp":1788778808222,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014452","name":"University of Cincinnati-College of Medicine","doi-asserted-by":"crossref","award":["F102150"],"award-info":[{"award-number":["F102150"]}],"id":[{"id":"10.13039\/100014452","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["DK112934"],"award-info":[{"award-number":["DK112934"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.molmet.2018.07.012","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T17:12:15Z","timestamp":1534785135000},"page":"28-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia"],"prefix":"10.1016","volume":"17","author":[{"given":"Belen","family":"Rivero-Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4444-0169","authenticated-orcid":false,"given":"Jenna","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Khrisna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-5480","authenticated-orcid":false,"given":"Kirk","family":"Habegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D'Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Perez-Tilve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2018.07.012_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2017.02.008","article-title":"The role of pancreatic preproglucagon in glucose homeostasis in mice","volume":"25","author":"Chambers","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib2","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1073\/pnas.0237106100","article-title":"Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice","volume":"100","author":"Gelling","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00125-006-0481-3","article-title":"Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia","volume":"50","author":"Conarello","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2018.07.012_bib4","doi-asserted-by":"crossref","first-page":"14972","DOI":"10.1073\/pnas.1205983109","article-title":"'Metabolic manifestations of insulin deficiency do not occur without glucagon action","volume":"109","author":"Lee","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/db10-0426","article-title":"Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice","volume":"60","author":"Lee","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2337\/db13-0710","article-title":"Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib7","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.1424934112","article-title":"Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway","volume":"112","author":"Wang","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13828","article-title":"Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist","volume":"5","author":"Damond","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.molmet.2018.07.012_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molmet.2016.05.014","article-title":"Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival","volume":"5","author":"Neumann","year":"2016","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib10","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1073\/pnas.1621069114","article-title":"Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice","volume":"114","author":"Okamoto","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib11","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1073\/pnas.94.13.6646","article-title":"Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2","volume":"94","author":"Furuta","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib12","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/db11-1605","article-title":"Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor","volume":"62","author":"Longuet","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI20911","article-title":"Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors","volume":"113","author":"Sloop","year":"2004","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2018.07.012_bib14","doi-asserted-by":"crossref","first-page":"15498","DOI":"10.1073\/pnas.1513872112","article-title":"Angptl4 links alpha-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism","volume":"112","author":"Ben-Zvi","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib15","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1073\/pnas.1620989114","article-title":"Angptl4 does not control hyperglucagonemia or alpha-cell hyperplasia following glucagon receptor inhibition","volume":"114","author":"Okamoto","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2017.05.011","article-title":"Interrupted glucagon signaling reveals hepatic alpha cell Axis and role for L-glutamine in alpha cell proliferation","volume":"25","author":"Dean","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2017.05.006","article-title":"Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic alpha cell hyperplasia in mice","volume":"25","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.molmet.2018.07.012_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.celrep.2015.06.034","article-title":"Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of \u03b1-cell mass","volume":"12","author":"Solloway","year":"2015","journal-title":"Cell Reports"},{"key":"10.1016\/j.molmet.2018.07.012_bib19","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/db16-1303","article-title":"Hypoglycemic effect of combined ghrelin and glucagon receptor blockade","volume":"66","author":"Mani","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.09.014","article-title":"Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease","volume":"167","author":"Finan","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.molmet.2018.07.012_bib21","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1093\/nar\/23.24.5080","article-title":"A\u00a0cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells","volume":"23","author":"Schwenk","year":"1995","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.molmet.2018.07.012_bib22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cmet.2014.04.005","article-title":"The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs","volume":"19","author":"Smith","year":"2014","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/cb1002015","article-title":"A\u00a0novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1","volume":"6","author":"Patterson","year":"2011","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.molmet.2018.07.012_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35093131","article-title":"CREB regulates hepatic gluconeogenesis through the coactivator PGC-1","volume":"413","author":"Herzig","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2018.07.012_bib26","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1016\/S0021-9258(18)98409-7","article-title":"Identification of a promoter element which participates in cAMP-stimulated expression of human insulin-like growth factor-binding protein-1","volume":"268","author":"Suwanichkul","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2018.07.012_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/db14-1052","article-title":"Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production","volume":"64","author":"Jun","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib28","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00042.2009","article-title":"Glucagon acts in a dominant manner to repress insulin-induced mammalian target of rapamycin complex 1 signaling in perfused rat liver","volume":"297","author":"Baum","year":"2009","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib29","doi-asserted-by":"crossref","first-page":"54103","DOI":"10.1074\/jbc.M410755200","article-title":"Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase","volume":"279","author":"Kimball","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2018.07.012_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.13-237743","article-title":"Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2)","volume":"28","author":"Lamming","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.molmet.2018.07.012_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMra1215228","article-title":"Mechanisms of hypoglycemia-associated autonomic failure in diabetes","volume":"369","author":"Cryer","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2018.07.012_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/eje.0.1510531","article-title":"The glucagonoma syndrome and necrolytic migratory erythema: a clinical review","volume":"151","author":"van Beek","year":"2004","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.molmet.2018.07.012_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00000441-200105000-00003","article-title":"The glucagonoma syndrome: a review of its features and discussion of new perspectives","volume":"321","author":"Chastain","year":"2001","journal-title":"The American Journal of the Medical Sciences"},{"key":"10.1016\/j.molmet.2018.07.012_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.molmet.2018.07.012_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00125-015-3794-2","article-title":"Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes","volume":"59","author":"Steenberg","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2018.07.012_bib36","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.2337\/db06-0307","article-title":"Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function","volume":"55","author":"Sorensen","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib37","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/dom.13202","article-title":"Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial","volume":"20","author":"Pettus","year":"2018","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cmet.2012.03.015","article-title":"Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c","volume":"15","author":"Hagiwara","year":"2012","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib39","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.1073\/pnas.1412047111","article-title":"Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21","volume":"111","author":"Cornu","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.07.012_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/db11-0739","article-title":"Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides","volume":"61","author":"Watanabe","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib41","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1210\/me.2009-0296","article-title":"Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells","volume":"23","author":"Hayashi","year":"2009","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.molmet.2018.07.012_bib42","article-title":"Endocrinology Diabetes Metabolism Case Reports","volume":"2016","author":"Larger","year":"2016","journal-title":"Endocrinology Diabetes Metabolism Case Reports"},{"key":"10.1016\/j.molmet.2018.07.012_bib43","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.molmet.2018.07.012_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/dom.12408","article-title":"Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function","volume":"17","author":"Kim","year":"2015","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1006\/bbrc.2001.6265","article-title":"Glycemic control in mice with targeted disruption of the glucagon receptor gene","volume":"290","author":"Parker","year":"2002","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.molmet.2018.07.012_bib46","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1172\/JCI43615","article-title":"Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis","volume":"121","author":"Ali","year":"2011","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2018.07.012_bib47","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diab.44.6.626","article-title":"Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM'","volume":"44","author":"Dupre","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc13-1169","article-title":"Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges","volume":"37","author":"Ghazi","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2018.07.012_bib50","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2337\/db10-1790","article-title":"Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function","volume":"60","author":"Kielgast","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.07.012_bib51","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2018.07.012_bib52","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc15-1643","article-title":"Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies","volume":"39","author":"Kazda","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2018.07.012_bib53","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/13543784.2017.1395020","article-title":"Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes","volume":"26","author":"Scheen","year":"2017","journal-title":"Expert Opinion on Investigational Drugs"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877818306495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877818306495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T21:23:19Z","timestamp":1661808199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877818306495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":53,"alternative-id":["S2212877818306495"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2018.07.012","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2018.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}